WO1999021415A1 - Nuclear transfer for production of transgenic animal embryo - Google Patents
Nuclear transfer for production of transgenic animal embryo Download PDFInfo
- Publication number
- WO1999021415A1 WO1999021415A1 PCT/US1998/022882 US9822882W WO9921415A1 WO 1999021415 A1 WO1999021415 A1 WO 1999021415A1 US 9822882 W US9822882 W US 9822882W WO 9921415 A1 WO9921415 A1 WO 9921415A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleus
- cell
- embryo
- transgenic animal
- donor
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 89
- 210000001161 mammalian embryo Anatomy 0.000 title claims abstract description 59
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 56
- 238000012546 transfer Methods 0.000 title claims description 88
- 238000004519 manufacturing process Methods 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 116
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 147
- 108090000623 proteins and genes Proteins 0.000 claims description 112
- 210000000287 oocyte Anatomy 0.000 claims description 65
- 108020004414 DNA Proteins 0.000 claims description 62
- 241000282898 Sus scrofa Species 0.000 claims description 59
- 238000000338 in vitro Methods 0.000 claims description 40
- 230000004913 activation Effects 0.000 claims description 27
- 241000283690 Bos taurus Species 0.000 claims description 24
- 230000010354 integration Effects 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 23
- 238000002744 homologous recombination Methods 0.000 claims description 19
- 230000006801 homologous recombination Effects 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 19
- 230000007159 enucleation Effects 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 239000003550 marker Substances 0.000 claims description 17
- 108700019146 Transgenes Proteins 0.000 claims description 15
- 210000000805 cytoplasm Anatomy 0.000 claims description 15
- 239000013612 plasmid Substances 0.000 claims description 15
- 238000011161 development Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 241001529936 Murinae Species 0.000 claims description 10
- 230000012173 estrus Effects 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 10
- 230000035800 maturation Effects 0.000 claims description 10
- 238000010449 nuclear transplantation Methods 0.000 claims description 8
- 230000006798 recombination Effects 0.000 claims description 8
- 238000005215 recombination Methods 0.000 claims description 8
- 108010091086 Recombinases Proteins 0.000 claims description 7
- 102000018120 Recombinases Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000034217 membrane fusion Effects 0.000 claims description 4
- 210000004340 zona pellucida Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 239000003710 calcium ionophore Substances 0.000 claims description 2
- 230000007910 cell fusion Effects 0.000 claims description 2
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 210000002257 embryonic structure Anatomy 0.000 abstract description 37
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 210000004940 nucleus Anatomy 0.000 description 70
- 239000013598 vector Substances 0.000 description 47
- 239000002609 medium Substances 0.000 description 40
- 238000005516 engineering process Methods 0.000 description 37
- 239000012634 fragment Substances 0.000 description 35
- 239000001963 growth medium Substances 0.000 description 32
- 230000008685 targeting Effects 0.000 description 29
- 210000002950 fibroblast Anatomy 0.000 description 25
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 24
- 238000004113 cell culture Methods 0.000 description 23
- 230000004927 fusion Effects 0.000 description 19
- 238000004520 electroporation Methods 0.000 description 18
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 229930182555 Penicillin Natural products 0.000 description 12
- 102000004142 Trypsin Human genes 0.000 description 12
- 108090000631 Trypsin Proteins 0.000 description 12
- 229940049954 penicillin Drugs 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 229960005322 streptomycin Drugs 0.000 description 12
- 239000012588 trypsin Substances 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 11
- 230000031864 metaphase Effects 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 210000004508 polar body Anatomy 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000002459 blastocyst Anatomy 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 7
- 210000001109 blastomere Anatomy 0.000 description 7
- 210000002308 embryonic cell Anatomy 0.000 description 7
- 238000010363 gene targeting Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 6
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940034629 chorulon Drugs 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 238000012239 gene modification Methods 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002406 microsurgery Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 230000001351 cycling effect Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000013020 embryo development Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 230000001360 synchronised effect Effects 0.000 description 5
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000001771 cumulus cell Anatomy 0.000 description 4
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 4
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 4
- LEOJDCQCOZOLTQ-UHFFFAOYSA-N dibutylcarbamothioyl n,n-dibutylcarbamodithioate Chemical compound CCCCN(CCCC)C(=S)SC(=S)N(CCCC)CCCC LEOJDCQCOZOLTQ-UHFFFAOYSA-N 0.000 description 4
- 230000006862 enzymatic digestion Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008672 reprogramming Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 3
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 108091006629 SLC13A2 Proteins 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012595 freezing medium Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 3
- 235000021251 pulses Nutrition 0.000 description 3
- 229940050570 regu-mate Drugs 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- VWAUPFMBXBWEQY-ANULTFPQSA-N Altrenogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC=C)C=C3)C3=C21 VWAUPFMBXBWEQY-ANULTFPQSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010052160 Site-specific recombinase Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 229960000971 altrenogest Drugs 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960004409 cloprostenol Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- -1 electroporation Substances 0.000 description 2
- 208000014616 embryonal neoplasm Diseases 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229950006344 nocodazole Drugs 0.000 description 2
- 210000004287 null lymphocyte Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 230000020509 sex determination Effects 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102100038075 Eukaryotic translation initiation factor 2D Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 238000003744 In vitro fertilisation Methods 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 102000057181 Sex-Determining Region Y Human genes 0.000 description 1
- 108700032475 Sex-Determining Region Y Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 208000012018 Yolk sac tumor Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000012791 bagels Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000408 embryogenic effect Effects 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108700020752 folligen Proteins 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 108010057342 ligatin Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010198 maturation time Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- YAHRDLICUYEDAU-UHFFFAOYSA-N methylhexaneamine Chemical compound CCC(C)CC(C)N YAHRDLICUYEDAU-UHFFFAOYSA-N 0.000 description 1
- 229950000752 methylhexaneamine Drugs 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000000986 microtubule polymerisation Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- FVGGCEANXXPWAJ-YXIHLITBSA-N n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-amino-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=CC=C1 FVGGCEANXXPWAJ-YXIHLITBSA-N 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003169 prostaglandin F2α derivatives Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229960004509 serum gonadotrophin Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8778—Swine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Definitions
- This invention relates to the generation of animals by nuclear transfer, including but not limited to the generation of transgenic animals.
- Nuclear transfer is the replacement of the nucleus of one cell with that Of another.
- the ability to produce live offspring by nuclear transfer is an objective which has been sought for some time by animal breeders.
- the ability to produce cloned offspring in such a manner would enable the production of large numbers of identioal offepring and the ability to genetically modify and/or select cell populations of the required genotype (e.g. sex or transgenic) prior to embryo reconstruction.
- a method of generating an animal embryo which method includes providing a donor nucleus, and a recipient cell; removing the nucleu ⁇ from the recipient cell; introducing the donor nucleus into the enucleated cell to produce a A tt ⁇ .1- r ⁇ c ⁇ B-stitmsgreeli; and
- the searchtit ⁇ to ' d'tell may be subjootod to a cell fueion/activation step.
- the voltage may be selected to simultaneously initiate activation.
- a method of generating a transgenic animal embryo said method including providing a donor nucleus which has been genetically modified to eliminate an undesirable activity or to provide for a desirable activily, and a recipient cell; transferring the donor nucleus to the recipient cell to produce a eo ⁇ * .+- rcsa ⁇ sWutad call; and C _.ou - ⁇ ⁇ l ⁇ • generating a transgenic animal embryo from said reeen m ⁇ titutac. eell.
- the animal embryo may be of any type, and i ⁇ oludec bird, fi ⁇ h, reptile and mammalian (including ungulato and primate) embryos including human embryos, e.g. murine, bovine, ovine or porcine embryos.
- the animal embryo Is a porcine embryo, bovine embryo, murine embryo or human embryo.
- tho transfer step includes removing the nucleus from the recipient call; introducing the donor nucleus into the enucleated cell to produce a MttohwiiutB-. call; and maintaining the wy ⁇ nia ut ⁇ uall in a suitable medium for a period sufficient to allow the cytoplasm to recover a substantially normal shape.
- the donor nucleus may be of any suitable type and from any suitable species.
- the donor nucleus may be contained in a karyoplast or cell,
- the donor nucleus may be of embryonic, embryonal tumor, foetal or adult origin.
- Donor nuclei may be prepared by removing the nucleus and a portion of the cytoplasm and pla ⁇ ma membrane surrounding it from early pre-implantation stage embryos (for example zygotes, 4- to 16* cell embryos) for example using microsurgery. When nuclei from more advanced embryonic cells are used the whole blastomere may be transferred to the recipient cytoplasm. Embryonic or foetal fibroblasts may be used.
- Embryonic stem (ES) cells [isolated from inner cell mass (1CM) cells, embryonic disc (ED) celi ⁇ or primordial germ cells (PGC)] may be used.
- a cell line derived from an embryonal tumor may be used (eg. embryonal carcinoma (EC) or yolk sac tumor cells).
- Adult celts such as fibroblasts may also be used. In this case the whole cell may be fused to the recipient cytopiasm.
- the recipient ceil may be of any suitable type and from any suitable species. Cytoplasts may be prepared from in vivo or in vrtro produced oocytes.
- Cytoplast ⁇ may be prepared from oocytes arrested in the second metaphase of meiotic maturation (Mil oocytes). Other sources of cytoplasts include zygotes, fertilised oocytes. and 2-cell blastomeres.
- Cytoplast preparation involves the removal of the nucleus in a process referred to as enucleatlon.
- the nucleus may be removed by microsurgery. This may Involve the removal of pronuclei or metaphase plate and surrounding cytoplasm from zygotes or oocytes, for example by aspiration or embryo bisection.
- Such manipulation may follow incubation of the zygotes or oocytes in a microfiiam ⁇ nt inhibitor, for example cytochalasin B (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.), that relaxes the cytoskeleton and allows the removal of a pomon of membrane enclosed cytoplasm containing the pronuclei or metaphase plate.
- cytochalasin B Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.
- nonphyslcal approaches such as inactivation of the
- cytoplasts e ore after or at approxmatey t e same me as onor nuc eue
- An animal embryo may be generated from the iLuuilUllt .J Lull by any ⁇ uilable method. Embryonic development may be initially in vitro and subsequently in ⁇ surrogate. Thus, the aMaa*w.u. g e e ⁇ ll may be initially cultured
- Activation occurs during fertilisation when the penetrating sperm triggers the resumption of meiosis. Activation is characterised by calcium oscillation,
- the donor 15 nucleus may be from an embryo that is itself the product of nuclear transplantation. This is known as serial nuclear transfer.
- Serial nuclear transfer may improve the capacity of differentiated nuclei to direct normal development. Whilst applicant does not wish to be restricted by theory, ⁇ erial nuclear transfer is postulated to improve the developmental capacity 20 of transplanted nuclei by allowing specific molecular components in the oocyte to assist ;in chromatln remodelling that is essential for nuclear reprogramming. Serial nuclear transfer is not restricted to a singular event but may be initiated on more than one occasion to sequentially improve conditions for chromatin remodelling, nuolear reprogramming and embryonic development
- the donor nucleus and recipient cytoplasm which are used in the method of the present invention may be of any suitable origin. Preferably, they are of porcine, bovine, murine or human origin. More preferably, they are from a MHC (SLA) : miniature swine because isogenic embryos and cell lines may be derived from such animals (see below).
- SLA MHC
- the method of the present invention may be used to generate transgenic animals, For example, a new gene may be expressed and/or an existing gene may be deleted in the transgenic animal. The addition ot new genes Is technically, less demanding than the deletion of existing genes.
- transgenic in relation to animals and all other species, should not be taken to be limited to referring to animals containing In their germ line one or more genes from another species, although many transgenic animals will contain such a gene or genes. Rather, the term refers more broadly to any animal whose germ line ha ⁇ been the eubject of teohnioal intervention by recombinant DNA technology. So, for example, an animal in whose germ line an endogenous gene has been deleted or modified (either by modifying the gene product or pattern of expression) Is a transgenic animal for the purposes of this invention, as much as an animal to whose germ line ⁇ n exogenous DNA sequence has been added.
- the donor nucleus may be genetically modified by modifying, deleting or adding one or more genes.
- the gene(s) to be modified, deleted or added may be of any suitable type.
- the ⁇ 1 ,3-galactosyltransferase gene may be modified in transgenic swine. This gene is non-funotional in humans and so it is no longer expree ⁇ ed. It does, however, still function in swine where its role is to add a specific sugar configuration to protein backbones. This glycosylation pattern is highly antigenic and humans carry high levels of antibodies to It.
- Swine -antigens to which humans react strongly are described as xenoantigens and the reactivity of humans towards swine antigens is described as xenoantigenicity.
- the net result is the immediate rejection of transplanted swine tissue in human recipients, inactivation, through gene modification, of the swine ⁇ 1 ,3-galactosyltransfera ⁇ e activity may make swine organs, tissues, or cells less susceptible to immune recognition following transplantation of said organs, tissues or cells Into humans.
- the process of modifying a gene may involve the introduction of one or more mutations in both copies of the target gene. Suitable cells y' take up the mutation(s) and then be used to generate an animal. One copy of the gene may be disrupted in the cell and the resultant heterozygous animals bred with each other until one with both copies of the gene mutated is found. Alternatively, both copies of the gene may be modified in vitro.
- a DNA construct including a nucleic acid sequence which is substantially isogenic to at least one or more portions of the target gene except for the introduction of the one or more mutations may, be used.
- the targeting DNA may comprise a sequence In which the desired sequence modifications are flanked by DNA substantially isogenic with a corresponding target sequence in the genome to be modified.
- the substantially isogenic sequence is preferably at least about G7- ⁇ 8% identical with the corresponding target sequence (except for the desired sequence modifications), more preferably at least about 99.0-99.5% identical, most preferably about 99.6% to 99.9% identical.
- the targeting DNA and the target DNA preferably share stretches of DNA at least about 75 base pairs that are perfectly identical, more preferably at least about 150 base pairs that are perfectly identical, even more preferably at least about 500 base pairs that are perfectly idcntioal.
- the targeting DNA is derived from cells of the same haplotype as the cells being targeted.
- the targeting DNA Is derived from cells of the same individual (or animal) as the cells being targeted.
- the targeting DNA sequence comprises at least about 100-200 base pairs of substantially isogenic DNA, more preferably at least about 300-1000 base pairs of substantially isogenic DNA, even more preferably at least 1000*15000 base pairs of substantially isogenic DNA.
- isogonio or ⁇ ubstantiaily ieog ⁇ nic DNA refers to DNA having a sequence that is identical with or nearly identical with a reference DNA sequence. Indication that two sequences are isogenic is that they will hybridise with each other under the most stringent hybridisation conditions (see e.g., Sambrook J., et al.. 1989); and will not exhibit sequence polymorphism (i.e. they will not have different sites for cleavage by restriction endonucleasos).
- substantially isogenic refers to DNA that is at least about 97-99% identical with the reference DNA sequence, and preferably at least about 99.5-99.9% identical with the reference DNA sequence and in certain cases 100% identical with the reference DNA sequence. Indications that two sequences are substantially isogenic is that they will ⁇ till hybridise with each other under the most stringent conditions ( ⁇ ee Sambrook, J., et al., 1989) and that they will only rarely exhibit restriction fragment length polymorphism (RF P) or sequence polymorphism (relative to the number that would be statistically expected for sequences of their particular length which share at least about 97-98% sequence identity).
- RF P restriction fragment length polymorphism
- sequence polymorphism relative to the number that would be statistically expected for sequences of their particular length which share at least about 97-98% sequence identity
- a targeting DNA sequence and a host cell sequence are compared over a window of at least about 75 consecutive nucleotides.
- DNA sequences compared between individuals of a highly inbred strain, such as the MHC Inbred miniswine, are generally considered to be substantially isogenic even if detailed DNA sequence Information is not available, if the sequence do not exhibit sequence polymorphisms by RFLP analysis.
- the donor nucleus may be genetically modified by modifying an endogenous gene In the donor nucleus.
- the endogenous gene may be modified by introducing into said donor nucleus a DNA construct including a nucleic acid sequence which is substantially isogenic to at least one or more portions of the endogenous gene and includes one or more mutations, such that there is homologous recombination between the DNA construct and the endogenous gene.
- a DNA construct tor modifying an endogenous gene in an animal nucleus said DNA construct including a nucleic acid sequence which Is substantially isogenic to at least one or more portions of the endogenous gene and includes one or more mutations.
- the endogenous gene is a swine, bovine, ovine, caprine or murine gene, more preferably a swine ⁇ 1 ,3-gaiactosyltransferase gene.
- the DNA construot is pGallaway, as hereinafter described or a functionally equivalent plasmid.
- plasmid By a functionally equivalent plasmid, we mean a plasmid capable of performing substantially the same function in substantially the same manner as the' plasmid in question. Without limiting the generality of the foregoing, other plasmid backbones are contemplated. Also, plasmids containing other portions of the swine 0.1 ,3-gatactosyltransferase gene and other mutations to that gene are contemplated.
- IRES :g ⁇ n ⁇ trap targeting vector may be selected from IRES-neo, IRES-lacZ,
- TAA3 IRES-lacZ
- TAA 3 IRES-lacZ lox neo-tk lox.
- TQ 3 IRES-lacZ mclneo.
- SA lacZ-IRES neo SA (TAAa) IRES-nuclear lacZ, SA (TAA3) IRES-nuciear lacZ lox Qprt lox, IRES- ⁇ geo, (TAA 3 ) IRES- ⁇ geo, SA IRES- ⁇ geo SA Optimised
- IRES- ⁇ geo IRES-nuclear ⁇ geo
- SA IRES-nuclear ⁇ geo
- SA (TAA 3 ) IRES-nuclear ⁇ geo.
- IRES gene trap targeting vectors provide ⁇ significant enhancement in gene targeting efficiency by eliminating a large proportion of random integration events. IRES gene trap targeting vectors rely upon functional integration into an actively transcribed gene (such as the target gene) for expression of the selectable marker. Random integrations Into non-transcribed regions of the genome are not selected.
- nucleic acid sequence which is substantially Isogenic to at least one or more portions of the endogenous gene and includes one or more mutations, and a selectable marker
- the endogenous gene Is a swine, bovine, ovine, caprine or murine gene, more preferably a swine ⁇ 1 ,3-galactosyltra ⁇ sferase gene.
- the DNA construct is pBERT 1 , as hereinafter described or a functionally equivalent piasmid.
- One approach is to flank the IRES selectable marker cassette with suitable DNA sequences which act as recombination sites following the addition of a suitable site-specific recombinase.
- a suitable •recombinase site Is the lox site which is specific for the Ore recombinase protein.
- Another example of a suitable recombinase is the FLP/FRT recombinase system (O'Gorman, S., et l., 1991).
- DNA construct for modifying an endogenous gene in an animal nucleus said DNA construct including a nucleio aoid s ⁇ quenoe which is substantially isogenic to at least one or more portions of the endogenous gene and includes one or more mutations a selectable marker, and recombination sites flanking said selectable marker, such that functional integration of said DNA construct into said endogenous gene results in expression of the selectable marker and addition of a recombinaee results in removal of the selectable marker by recombination at the recombination sites.
- the endogenous gene ia a ewine or murine more preferably a swine ⁇ 1 ,3-galactosyltransferase gene.
- the endogenous gene ia a ewine or murine more preferably a swine ⁇ 1 ,3-galactosyltransferase gene.
- DNA construct is pBERT 11 , as hereinafter described or a functionally equivalent plasmid.
- the DNA constructs according to this aspect of the invention may be engineered in bacteria and then introduced into the ceils.
- the transgenes may be introduced into the cells by any suitable method. Preferred methods include direct injection, electroporation, liposomes or calcium phosphate precipitation. Direct Injection Is the preferred method for embryonic cells while electroporation is more suitable for embryonic fibroblast and embryonic stem cell cultures. Whilst applicant does not wish to be restricted by theory, it is thought that regions of substantially isogenic DNA either side of the mutation drag the transgene to the target site where it recombines and introduces the mutation. It Is further thought that the main contributing factor for increasing the efficiency of introducing a specific mutation in a given gene is the degree of similarity between the target DNA and the introduced DNA. Thus, it is preferred that the DNA is isogenic (genetically identioal) not allogenic (genetically dissimilar) at the genetic locu ⁇ that is to be targeted.
- an animal embryo or tran ⁇ genic animal embryo produced by the methods of the present invention.
- the animal embryo or transgenic animal embryo is a porcine, murine, ovine, bovine, caprine or human embryo.
- a reconstituted animal cell or modified reconstituted animal cell produced by the methods of the present Invention is provided.
- the reconstituted animal ceil or modified reconstituted animal cell is a porcine, murine. ovine, bovine, caprine or human cell.
- an animal or transgenic animal produced by the methods of the present invention.
- the animal or transgenic animal is a porcine, murine, ovine, bovine, caprine or human animal, more preferably a MHC(SLA) miniature ⁇ wine.
- Figure 1 A shows an overview of a nuclear transfer procedure according to the present invention in which activation occurs prior to enucieation which is then followed by a quiescent period of, e.g. 6 hours and ther fusion.
- Figure 1B shows an overview of a nuclear transfer procedure according to the present invention in which recipient cells are enucleated, subjected to a quiescent period of, e.g. 6 hours and thenjcomblned fuslon/actlvation.
- i Figure 2 summarises the steps taken for construction of the pGallaway targeting vector. ⁇ «. ( •**; /* ⁇ ?C » o ⁇ -*>• «>-; ⁇ . «,-, 7j «_ C*J * %_ G»/l «. «.Ji V t
- Figure 3 ie a map of pBERT.
- Figure 4 is a map of the linker referred to in Example 3.
- Figure 5 shows the modifications to Intron 8 and exon 9.
- Figure 6 shows the genomic organisation of the swine ⁇ 1 ,3-galacto ⁇ yltransferase gene following a homologous recombination event between the chromosomal locus and the pGallaway vector.
- Figure 7 shows the strategy used to identify mutant transfectants.
- Figure 8 shows a PCR analysis of the transfectants obtained in Example 3.
- Figure 9 shows the results of Ase 1 digestion of mutant PCR products.
- Figure 10 is a map of pBERT 1.
- Figure 11 is a map of pBERT 11.
- Figure 1 shows transgenic animals generated by nuciear transfer.
- Figure 13A shows an RT-PCR analysis of the transfectants obtained In Example 5.
- Figure 13B shows the results of an RT-PCR analysis of the transfectants obtained in Example 5 after Ase 1 digestion.
- Figure 14 shows a strategy developed for sorecning for targeted colonies referred to in Example 12.
- Cytoplasts were prepared from either in vivo or in vitro produced oocytes collected from both outbred and HC (SLA) inbred miniature swine. Whilst applicant does not wish to bo restricted by theory, it is thought that the use of the MHC (SLA) inbred miniature swine oocytes as a source of cytopiasts will be beneficial in reducing mitochondrial DNA chimaerism and extraneous agents present In the cytoplast.
- SLA MHC
- a number of systems have been developed to synchronise and superovulate swine to obtain a large number of oocytes required for cytoplast preparation. These systems can be used in both outbred and MHC (SLA) miniature swine. Synchronisation of the estrous cycle was achieved by the following treatments: 1. administration of synthetic progesterone (eg. Regumate, Altre ⁇ ogesl. Hoechst-Roussel); 2. prostaglandin or prostaglandin analogue injection of a pregnant swine; 3. removal of offspring at weaning. Natural cycling swino was also used.
- synthetic progesterone eg. Regumate, Altre ⁇ ogesl. Hoechst-Roussel
- prostaglandin or prostaglandin analogue injection of a pregnant swine 3. removal of offspring at weaning. Natural cycling swino was also used.
- Superovuiation with follicle etimuiating hormone (FSH) wa ⁇ used to increase the number of oocytes obtained from each ovary.
- FSH activity of pregnant mares serum gonadotrophin (PMSG, Folligen, Intervet (Aust) Pty. Ltd. or Pregnecol, Horizon Technology Pty. Ltd. 750 -1500 IU) is preferred.
- Ovuiation time was controlled with the injection of human chorionic gonadotrophin (hCG (Chorulon, Intervet (Aust) Pty. Ltd., 500 IU).
- Unfertilized metaphase 11 oocytes were surgically collected 2-16 hours after ovuiation. In vitro oocyte production
- OCC Oocyte cumulus comploxe ⁇
- OCC were cultured in microdrops or Nunc 4-well tissue culture plates of one of the above oocyte maturation medium or any other suitable medium overlaid with mineral oil (Sigma Chemical Company, Slgma-Aldrlch Pty. Ltd.). at 38.5°C* under 5%CO ⁇ In air for 48-50 hours.
- Each medium was supplemented with 10% Estrus cow serum (Day 0 to 5 after standing heat) and 0.01 units/ml Follicl Stimulating Hormone ( from porcine pituitary, Sigma-Aldrich Pty. Ltd.)
- the benefits of adding of Eetrus cow serum is shown in Table 2.
- ECS Estrus Cow Serum
- FBS Fetal Bovine Serum " Basic medium, TCM 199; Maturation time -48-52 hrs
- Recipient cytoplast were prepared by removal of metaphase chromosomes ⁇ o from mature metaphase II (Mil) oocytes. or both pronuclei (PN) from in vivo fertilised oocytes for the first and second round of nuclear transfer respectively.
- the enucleation pipette was positioned Just below the first polar body. Gentle suction was applied into the enucleation pipette to remove a proportion (approximately 1/3 to 1/6) of the oocytes cytoplasm and the first polar body. Successful enuoieation was confirmed by the detection - of the metaphase plate in the removed cytoplasm and first polar body by exposing the enucleation pipette to UV light. Care was taken to avoid exposure of the enucleated oocyte to UV. In mouse experiments the first polar body was rarely removed as it is undergoing degeneration al this particular time. This enucleation procedure was performed at room temperature.
- the oocyte was exposed to UV ( ⁇ 15 seconds) to allow for visualisation and orientation of the metaphase II plate. Following enucieation the oocyte and confirmation of enucleation was identical to the methods described above.
- Cytoplast from the second round of nuclear transfer were prepared from in vivo sourced zygotes. Donor female gilts or ⁇ wine were synchronised and supcrovulated as described above. Females were mated with males twice, 24 hours and 32 hours after hCG (Choruion, Intervet (Aust) Pty. Ltd.) injection. Zygotes couid also produced by in vitro fertilisation of in vitro matured oocytes.
- Fertilised oocytes have two pronuclei: male and female pronuci ⁇ u ⁇ (PN), which appear 4-8 hours after fertilisation.
- the developing pronuclei are normally obscured by the htgh content of lipids present In swine embryos.
- Visualisation of the PN was achieved by ce ⁇ trifugation (6-12 min. B.000-15.000g), Ce ⁇ trifugatio ⁇ stratifies the lipids and allowed both PN to be easily removed by enucieation techniques. Cumulus cells still adhered to the zona pellucida were removed by incubation in hyaluronidaee (300iu mi) for approximately five minutes.
- Cytoplasts for the purpose of serial nuclear transfer were prepared from zygote ⁇ 44-50 hours after hCG (Chorulon, Intervet (Aust) Pty. Ltd.) administration. Fertilised oocyte ⁇ were incubated in cytochalasin B (Sigma-Aldrich Pty Ltd) In a manner similar to that described for Mil oocyte enucleation, both PN were removed by microsurgery. No DNA staining was required to confirm the removal of PN since they were clearly visible in the enucleation pipette.
- oocytes were denuded of cumulus cells by gentle pipetting or digestion in hyaluronidase (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.. 300 lU/ml in H-G1 medium or other short term handling medium) and stained in UV fluorescent DNA dye H ⁇ echst 33342 (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd., 5 ⁇ g/ml) for approximately 10 minutes at 39 ⁇ C. Metaphase ll oocytes were selected .
- the zone pellucida was partially dissolved by ⁇ short in ⁇ ubation in 0.1% prona ⁇ e (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.) and removed by a gentle passage through a narrow pippette.
- the oocytes were incubated 15 min in H-G1 or other short term medium with cytochalsln B (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.) (1.0 - 7.5 ⁇ g/ml) and enucleated by bisection Into two halves (Tarkowski, 1977).
- the nucleus was likely to be located in close proximity to the first polar body.
- Phytohemagglutinin was used to stick the polar body to the cytoplasm membrane.
- the enuole ⁇ ted halves identified under UV illumination by the absence of chromatin stained with Hoechst (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.), were washed and stored in H-Gl medium or other short term medium until used for fusion (46-50 hours after the onset of oocyte maturation).
- Karyopiasts from the following source ⁇ were Used: 4- to 16-cell embryos (embryonic nuclei), embryonic foetal, and adult (sematic) fibroblasts, embryonal tumour (Embryo Carcinoma) and embryonic stem cells (Isolated from Inner cell mass cells), embryonic disc cells, or primordial germ cells.
- Preimplantation embryos at 4 to 16-cell stage were collected from the reproductive tracts of superovulated and mated female miniswines. Superovuiation was induced as described in Example 1. Foetuses for PGC isolation were collected from 25 to 35 day pregnant female mlnlswine following superovuiation or natural cycling and mating (Example 1).
- telomeres Four to 16-cell stage embryos were collected using standard surgical procedures 94 to 144 hours after hCG (Chorulon. Intervet (Aust) Pty. Ltd.) injection.
- Karyoplasts containing embryonic nuclei were obtained by removing a portion of the cytoplasm which contained the nucleus of the biastomere. This was performed by microsurgery in a similar manner to that described above for cytoplast preparation.
- the embryo was incubated in a microfilament inhibitor (e.g. cytochalasin B. (Sigma Cell Culture, Sigma-Aldrich Pry.
- the whole blastomeres synchronised in the G2 or M- phase were used as the source of the karyoplasts.
- the ceil cycle consists of four phases: M (mitosis), GO. S (synthesis) and G2. Synchronisation of cell cycles between donor nuclei and recipient cytoplasts at the time of transplantation strongly influenced the development of reconstituted eggs.
- Foetuses were collected on day 25 to 35 of pregnancy from slaughtered female mini ⁇ wine, The uterus was removed and foetuses isolated using sterile techniques. The foetuses were decapitated immediately after isolation and washed in cold PBS (Oxoid, Unipath Ltd. UK). A small tissue sample was taken from each foetus for genotypi ⁇ g (by using PCR). The fibroblast cultures were established from lung, muscie/skin (mese ⁇ chymal) tissues as follows. Other tissues may also be used. The tissue from individual foetuses was disected, washed in PBS (Oxoid, Unipath Ltd.
- the culture medium was DMEM (Gibco BRL, Life Technologies Inc., US) supplemented with 10% FCS, 2 mM glutamine (Gibco BRL, Life Technologies inc. US), 100 lU/rnl penioillin (Giboo BRL, Life Technologies inc, US), 100 ⁇ g stroptomyoin (Giboo BRL, Life Technologies inc. US), 0.1 mM ⁇ mercapto ethanol (Gibco BRL, Life Technologies inc. US).
- Other types of media or protein/growth factors may also be used (e.g.
- DMEM Gibco BRL, Life Technologies Inc., US
- F12 Gibco BRL, Life Technologies Inc. US
- DMEM Dulbecco's modified Eagle's medium
- FCS CSL Limited, Aus
- 100 IU/ml penicillin Gibco BRL, Life Technologies Inc. US
- 100 ⁇ g/ml streptomycin Gibco BRL, Life Technologies inc. US
- 2 mM glutamine Gibco BRL, Life Technologies Inc. US
- 0.1 mM mercaptoethanol Gibco BRL, Life Technologies Inc. US).
- gelatin Sigma Cell Culture, Sigma-Aldrich Pty, Ltd.
- water 0.1% gelatin (Sigma Cell Culture, Sigma-Aldrich Pty, Ltd.) in water.
- a bovine foetus (CR length 7.5 cm) was collected from an abattoir - slaughtered cow. The foetus was washed In 3 changes of cold PBS containing 100 lU/mi penicillin, 100 ⁇ g streptomycin (PBS-P/S) eviscerated and washed again in 3 changes of cold PBS-P/S. Fibroblast cultures were established from superficial skin (BEF-S) and from muscle (mesenchymal; BEF-M) tissues as follows.
- the superficial skin was peeled off from hind and front legs and the muscle tissue was disected from hind legs, washed in 2 changes of cold PBS-P/S, disaggregated mechanically by chopping with scalpel blades followed by enzymatic digestion.
- enzymatic digestion ti ⁇ uee were incubated for 90 min (or up to 4 - 6 hr) at 4 ⁇ C in 0.25% trypsin / 0.04% EDTA in PBS. After removing the excess of trypsin, tissues were incubated at 37°C for 10 - 20 min, culture medium was added and cells dissagregated by vigorous pipetting. Large, undigested pieces of tissue were allowed to settle by sedimentation.
- PBS sterile solution of PBS (Ca * and g" free) supplemented with 100 lU/mi penicillin, 100 ⁇ g/ml streptomycin
- Freezing medium 10% DMSO, 90% culture medium or FCS Sex determination
- the sex of the isolated fibrobla ⁇ t ⁇ was determined by PCR (Pomp et al J, Anim Sci 1995; 73: 1408-1415). Two genes were amplified in a singie reaction:
- the cells were found to be isolated from male foetus.
- Muscle tissue derived fibrobla ⁇ t ⁇ were u ⁇ ed to introduce gene markers: ⁇ - galactose gene and/or neomycin gene.
- the cell line, BEF-M was transfected by electroporation with the following vectors:
- the positive 6PLacZ TIN ⁇ S-MO clones were analysed for the expression pattern of ⁇ -galactosldase gene by staining with X-gal.
- Ear samples were collected from adult male and female miniature ⁇ wine.
- the tissue samples were briefly sterilised in 70% ethanol and washed in 3 changes of cold PBS containing lOO IU/ml penicillin, 100 ⁇ g streptomycin (PBS- PIS).
- PBS- PIS cold PBS containing lOO IU/ml penicillin, 100 ⁇ g streptomycin
- the fibroblast cultures were established from skin as follows: The skin was disaggregated mechanically by chopping with scalpel blades followed by enzymatic digestion. For enzymatic digestion tissues were incubated for 5 hr (or up to 12 hr) at 4 e C in 0.25% trypsin / 0.04% EDTA in PBS.
- tissues were incubated at 37 ⁇ C for 30 min, culture medium was added and cells dissagregated by vigorous pipeting. Large, undigested pieces of tissue- were allowed to settle by ⁇ edimentation.
- Supernatant containing single cells was decanted and the ceils plated onto gelatinised (0.1% gelatin in water) Petrie dishes and cultured at 37 ⁇ C in an atmosphere of 5% CO 2 in air. This was passage 0 (PO).
- the medium was changed every 24 hours and the cells cultured until confluent (between 5 to 8 days). The cells were then expanded by trypsinization and passaging 10 5 to 10° cells onto a 10 cm gelatinised Petrie dish in culture medium.
- Trypsin 0.25% trypsin, Q.04% EDTA n PBS (without Pen/Strep)
- Freezing medium 10% DMSO, 90% culture medium or FCS
- the genetic modification of animal genomes can be broadly divided into random and targeted transgene integration.
- Whiie random transgene integration suffers considerable limitations attributable to unpredictable site of integration effects, targeted transgene integration offers significant improvement in current loss of function applications and significantly greater opportunity in enabling planned modification of specific endogenous genes.
- mice Targeted mutations in mice have been possible due to the availability of ES cell culture systems which are not available for other species.
- ES ceils which are isolated from the inner cell mass of preimplantation mouse embryos, can be extensively propagated in vitro without losing their capacity to contribute to all cell types of an animal.
- the in vitro propagation of ES cells provides an extremely valuable opportunity to introduce transgenes and select clonal cell lines having the desired transgene integration event. The selected cell line can then be used as a genetic resource to establish an equivalent transgenic animal.
- An alternate route to ES cell-mediated transgenesis is to couple in vitro cell culture and ge ⁇ elic manipulation with nuclear transfer.
- Nuclear transfer differs from ES cell-mediated transgenesis in that a variety of cell types that can be cultured and genctioally manipulated in vitro can be utilised as a genetic resource for the establishment of a new animal.
- embryonic fibroblasts which can be propagated and genetically manipulated in vitro are not pluripotential and cannot contribute to the germllne of an animal.
- the nuclei of genetically modified embryonic fibroblasts can be utilised as a genetic resource to establish a transgenic animal by reprogramming the developmental capability of that nucleus through nuolear transfer.
- fertilised oocytes or eingle cells of in vitro or in vivo produced embryos can be cultured, genetically modified and used as a genetic resource for generating transgenic animals by nuclear transfer or aggregation with host embryos.
- Endogenous genes are not limited to the examples shown. Gene targeting and nuclear transfer in swine and other animals would also be useful in cases of:- 1 ) Removal (knockout) of genes responsible for boar-*taint,
- Genomic DNA from ⁇ d/d miniswi ⁇ c shown to be homozygoue at the ⁇ 1 ,3-galactoeyltransfera6e locus by RFLP analysis was used to conetruct a genomic library. The same swine was used for derivation of the target cells used in these studies, assuring isogenicity and target locus.
- the lambda genomic library was made from DNA Isolated from liver tissue using the Promega LambdaGEM-12 Xho I Half Site Arms (Promega Corp., Madison, WI) protocol with modifications. The genomic DNA was partially digested with Sau 3A I followed by partially filling-in of the Sau 3A I as described by Promega.
- the DNA fragments were then size fractionated by agarose gel electrophoresis using standard methodologies.
- the DNA was ligated to LambdaGEM-12 vector, which had already been digested with Xho I and dephosphorylated; and the first two nucleotides of the Xho I site filled in.
- the ligated DNA was packaged using the Stratagene Gigapack Gold Packaging Extract and mixed with E.coli host strain, KW261 ,
- the genomio library contained approximately 2 x 10 6 independent donee.
- the unamplified library was screened with a 240 bp PCR fragment corresponding to nucleotides 607 througn 847 of porcine ⁇ 1 ,3-galactosyltransferase gene (GT, Strahan et al. 1995.- immunoge ⁇ etics, vol. 41 : 101-105, cDNA Sequence and Chromosome Localization of swine ⁇ l ,3-gaiactosyitra ⁇ sferase, Ge ⁇ bank Accession Number L36152) using standard methodologies.
- Six bona tide porcine ⁇ l ,3-galactosyitransferase clones were identified and mapped by Southern analyses using standard methodologies. Two clones (#12 and 4) were selected for use in construction of the targeting vector, pGallaway.
- lambda clones were subcloned as follows: lambda clone 12 was digested with Eco RI and the 10 kb fragment containing GT sequences upstream of exon 9 was isolated. This fragment was cloned into pUC19 Eco RI cut vector to generate pTCL12-45 (orientation 1) and pTCL12- 0 (orientation 2). Lambda clone 4 was digested with Sac I and the 11.8 kb fragment containing GT sequences downstream of exon 9 was isolated, then cloned Into pNEB 193 (NEB) Sac I cut vector to generate pTCR4-9.
- a 2.8 kb Eco Rl/Sac I fragment was also isolated from lambda clone 12 and cloned into pNEB 193 Eco Rl/Sac I cut vector to generate 4-2. This fragment contains 3' intron 8 sequences and 5' exon ⁇ sequences. Together, the 10 kb Eco RI fragment (clone 12), the 2.8 kb Eco Rl Sac I (clone 12) and the 11.8 kb Sac I fragment (clone 4) form a 24.6 kb contiguous fragment containing the porcine GT extending from Intron 7 through exon 9 Into sequences 3' of GT.
- linker (comprised of oligonucieotides 5'-TCG ACT GTT TAA ACG GCC TCT ACG GCC TAG CT-3'
- the vector, 4-2A was digested with Eco RI and Sac I and the 2.8 kb Eco
- Rl Sac I fragment containing the modified Bse RI region was isolated.
- Vector. pTCL12A was digested with Eco RI, daphosphorylated, and ligated together with the 4-2A Eco Rl Sao I fragment. Tho ligatin reaotion was first digested with Pme I, then with Sac I, and the 9-10 kb Pme l Sac I fragment was purified.
- the vector, pTCR4-9 was digested with Not I, daphosphorylated, digested with Sac I and the resulting 11 kb Sac I/Not I fragment was purified.
- the vector (SuperCos) Stratagene), was digested with Eco RI, which was filled-in with Klenow, then digested with Xba I and the 6.5 kb SuperCos ori fragment isolated.
- the four purified fragments 6.5 kb SuperCos ori (Eco RIVXba I; 12.6 kb SuperCos:stuffer Xba l/Not I; 9-10 kb TCL12A/4-2A Pme l/Sac I; and 11 kb TCR4-9 Sac l/Not I were ligated together in a two-step ligation
- the TCL12A/42A fragment was first ligated to the TCR4-9 fragment and then the remaining two fragments were added to the ligation.
- the ligation mixture was packaged as described earlier. Clones were screened using standard methodologies and one correct clone, pBERT was used for further work.
- pTCL12-40 was digested with Eco RI, which was filled-in with Klenow, followed by digestion wilh Xho I. The resulting 6.5 kb fragment containing the 5' GT region was purified.
- the recipient vector (pOCUS/pgk-neo) is a modified pOCUS vector (Novagen) which contains a pgk-neo cassette cloned into the Hinc II site of pOCUS.
- a partial Spe I digest was carried out on pOCUS/pgk- ⁇ eo, the linearized Spe I vector punfied, then digested with Xho I. The resulting 3.7 kb fragment containing the vector was purified and ligated to the 6.5 kb (Eco RlVXho I fragment from pTCL12-40 to generate pEddie.
- the 3' GT region was cloned into pEddie as follows: pEddie was digested with Xho I and Not I, dephosphorylated and the 10 kb fragment purified. pBert was digested with Xho I and Not I which removed the 18.1 kb QT region (with stop codon modifications) from the vector backbone. The unpurified 18.1 kb Eco Rl/Not I fragment was ligated to the pOCUS/pgk-neo Eco Rl/Not l vector. The ligated DNA was electroporated into competent E.coli TOP10 cells and individual colonies screened by standard methodologies. One correct pGallaway clone was Identified and was used for further work.
- pGallaway can be used as both a replacement or insertion vector.
- Either the unique Xho I or Sal I sites within the GT region can be used to linearize pGallaway for use as an insertion vector.
- the entire 24.6 kb GT region can be removed from vector sequences by digestion with Sfi I and Not I.
- the line must be isogenic with the vector.
- the line can be immortalised to permit sufficient pa ⁇ age between the initial transfection and subsequent analyses.
- the line should express the ⁇ 1 ,3-galacto ⁇ yltran ⁇ fera ⁇ e gene, as expression will be required for the homologous recombination assay.
- the line must be transfectabl ⁇ and selectable at reasonable frequencies.
- Aortic endothelial cells from the same miniature swine used to derive the genomic DNA library were Immortalised with SV40 T antigen (Seebach et al., 1997, The 4th intemationai Congress for Xenotransplantatio ⁇ , France).
- One of the ceil lines, P ⁇ DSV15, which satisfied the criteria listed above, was transfected by electroporation with the pGallaway targeting vector. The vedor was linearized at a unique Xho i restriction site.
- the cell suspension was then transferred to 10 ml of standard medium (M1G9 containing 10% fetal bovine eerum (Life Technologies, Gaithersburg, MD) and pelleted.
- the cell pellet was resuspended and plated in enhanced medium (M199, 20% FBS, 100 ⁇ g/ml Endothelial Cell Growth Supplement (Collaborative BioMedical, Bedford,- MA)) at approximately 6 x 10* cell/cm' in various size plates to generate pools with varying numbers of stable transfectant clones, a limiting dilution series was performed to determine the stable transfection frequency for extrapolation of stabie ations/pl ⁇ t ⁇ .
- the oells were re-fed enhanced medium containing 400 ⁇ g/ml Gcnctioin (Life Technologies, Gaithersburg, MD) and ⁇ elected for 10-14 days.
- transcripts are most readiiy identified by RT-PCR using a forward primer from an ⁇ 1 ,3-galactosyltra ⁇ sferase exon upstream of the vector sequences and a reverse primer specific for amplification of the expected mutant transcript.
- the forward primer chosen for these experiments was derived from wild-type exon 7 sequence.
- the reverse primer was ds ⁇ ved from the mutated region of exon 9 In the pGallaway vector, and has a 3' terminal mismatch to the wiid-type ⁇ ! ,3-gaiactosyitransferase sequence.
- RNA was prepared from stable transfectant cells using the RNeasy Isolation Kit (Qiagen, Chatsworth, CA) according to the manufacturer's instructions.
- cDNA was prepared from RNA using the Superscript Pr ⁇ amplification System (Life Technologies, Gaithersburg, MD), using random hexamers according to the manufacturer's instructions.
- cDNA was amplified in 100 PI reactions containing 10 mM Tris-HCl pH 8.3, 50 mM KCI, 10 ⁇ M each dNTP. 0.9 mM MgCI 2 . and 25 ⁇ /ml Amptitaq Gold polymerase '(Perkln-Elmer, Norwalk. CT).
- Forward primer F238 5'-TTA CCA CGA AGA AGA AGA CGC-3' (SEQ ID NO;3) and reverse primer RD2 5'-TGC AGA TAT TCA GAA CTC CTC CT-3' (SEQ ID NO:4) were present at 200 nM.
- Amplification reactions were performed using a System 9600 thermocycler (Perkin-Elm ⁇ r, Norwalk, CT) with the following profile: 3) 95°C for 9 min.
- the cDNA reaction was amplified with wild type primers F238 and R545 5'-AQA TGA CTT TGT GGC CAA CC-3' (SEQ ID NO:5), from porcine ⁇ 1 ,3-galactosyltransferase exons 7 and 9 respectively.
- the mock cDNA reactions were amplified with primers F23B and RD2.
- the cDNA reactions were amplified with p ⁇ mers F238 and RD2.
- RNA from the 2 * 3 pool prior to selection was resistant to ly ⁇ ie.
- RT-PCR analysis was performed on RNA from the 2 * 3 pool prior to selection and after five rounds of selection. As expected from the size of the pools, only wild type PCR product was detected in the 2 * 3 pool prior to selection. Following selection, the vast majority of PCR product was that expected from the targeted aliele.
- IRES gene trap targeting vectors provide a significant enhancement in gene targeting efficiency by eliminating a large proportion of random integration events. IRES gene trap targeting vectors rely upon functional integration into an actively transcribed gene (such as the target gene) for expression of the selectable marker. Random integrations Into ⁇ on-tran ⁇ cribed regions of the genome are not seiected.
- FIG. 10 shows ' one ⁇ 1 ,3-gaiadosyltransferase IRES gene trap targeting vector for f unotiqn ⁇ l disruption of ⁇ 1 ,3-galadosyltransf erase gene expression, in a preferred embodiment, it may be deeirablo to remove the selectable marker cassette from the targeted locus to eliminate expre ⁇ ion of the antibiotio resistance gene.
- FIG. 11 shows one example of ⁇ recombinase sensitive ⁇ 1 ,3-galactosyltransferase IRES gene trap targeting vedor for fundional disruption of ⁇ 1 ,3-galactosyltransferase gene expression.
- High efficiency gene targeting and selection has a significant advantage in that suitably stringent selection systems, such as the IRES gene trap targeting vectors, can eliminate the need for biochemical analysis of clonal cell lines.
- individual nuclei from a pool of uncnaracterised transgenic cells should generate offspring of the desired phenotype at a ratio equivalent to the selected pool.
- the elimination of clo ⁇ al selection may be particularly useful where only limited in vitro propagation is desirable or possible.
- One such instance includes the culture of embryonic nuclei for nuclear transfer. Embryonic nuclei are more efficient than latter stage somatic cells for generating live bom offspring by nuclear transfer, however, totipotentiai embryonic cells can not be cultured for extended periods for any other species than mice. Nuclear recycling of embryonic nuclei (see following) provides an opportunity to maintain, expand and genetically manipulate multipotential cells from swine in vitro in the absence of typical ES culture systems.
- Transgenes may be introduced into cultured ceils or embryos by direct injection, ciedroporation, liposomes or calcium phosphate precipitation.
- Direct injection is ⁇ the preferred method for individual embryonic cells while electroporation is more suitable for embryonic fibroblasts and embryonic stem ceils.
- plasmid DNA for electroporation was linearised by restriction enzyme digest, ethanol precipitated and resuspended at 1.0 mg/ml in PBS (Oxoid, Unipath Ltd. UK). Following 2 hours culture in fresh medium, near confluent cells were dispersed by trypsinisation, washed sequentially in culture medium and PBS (Oxoid, Unipath Ltd.
- a 200 V, 960 ⁇ F oh ⁇ rge was then applied with a Gene Pulser II apparatus (Blo-Rad Laboratories). After 10 min incubation at room temperature the cell suspension was transferred to 10 mi of culture medium and plated onto a number of 10 cm Petrl dishes. The cells were re-ted culture medium containing 400 ⁇ g/ml Geneticin (Life Technologies) and selected for 8 to 14 days.
- mutant (primers F338 and RD2) to identify the cells producing the mutant transcript expected from the homologous recombination of pGallaway and the endogenous ⁇ 1 ,3-gaiactosyltran ⁇ fera ⁇ e locus.
- the "master" plate is frozen as follows: When tne cells reach confiuency, the medium Is removed and cells briefly washed with PBS, and 0.25% trypsin, 0.4% EDTA In PBS. The plate Is then put on ice and 500 ⁇ l of cold freezing medium (10% DMSM. 80% FCS) added to each well. The plate Is stored for up to 2 to 4 weeks at -75*0 or after 24 hr al -75'C transferred to liquid nitrogen. To thaw the cells, the plate is transferred to room temperature, 500 ⁇ i of warm culture medium added to each well and the cell suspension transferred to a new 24 well plate. Tho cells are cultured at 37°C in an atmosphere of 5% C0 2 in air.
- Activation of the cytoplast was preferred for further embryonic development. Activation occurs during fertilisation and is characterised by a wells of Ca 2i oscillations, release of cortical granules, extrusion of a second polar body, pronuclear formation and ultimately cleavage. Development of an oocyte without fertilisation by sperm is known as parthenoge ⁇ ic activation. Parthenogenlc ootivation can be induced by various chemical and physical treatments such as ethanoi, calcium ionophore and electrical pulses (Ozil, J.P. 1990).
- the activated reconstituted oocytes were cultured . in vitro overnight (24 hrs), or to the biastocyst stage (Day 6) of development (Example 6) prior to transfer Into surrogate swine (Example 8)
- the nuclear transfer procedure involved the reconstitution of an enucleated cytopia ⁇ t with a karyoplast containing tho donor nucleus.
- Cytoplasts were reconstituted by inducing membrane fusion with the karyopia ⁇ t following treatment with chemical reagents, such as polyethylenegiyool (Czolowska et a!., 1984), or by exposure to electrical. pulses (Wllladsen 1986). Cytoplasts were also reconstituted by direct injedio ⁇ of the intact donor nucleus and karyoplast lysate Into the cytoplast (Bromhall 1 ⁇ 75; lllmensee and Hoppe 1981).
- cytoplast reco ⁇ stitulion was the preferred technique for cytoplast reco ⁇ stitulion.
- the parameters required for successful fusion depends on the origin of the karyoplast and also whether the zonae pellucida wae present on the cytoplast.
- the karyoplast was inserted into the perivltelll ⁇ e space (PV) of the cytoplast between the oocyte membrane and zone pellucida, with all manipulation performed in cytochalasin B (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd., 5 ⁇ g/ml).
- the cytoplast and karyoplast were placed between two platinum electrodes 0.5 - 1.0 mm apart in a solution of 0.3 M mannito! (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.), (Prather et al., 1989).
- the cytopiast and karyoplast were orientated In a perpendicular fashion so that the fusion plane of the two cells was parallel to the electrodes.
- An alignment current of 5-10 V AC 500-800 kHz for less than 1.0 s
- fusion was induced by a brief exposure to DCinstalle (30-120 V/mm for 50 - 300 ⁇ s). Fusion of the oytoplast and karyoplast was observed within 15 -30 minutes by loss of membrane distinction between cells.
- iCytopiast volume has been demonstrated to effed development of nuclear transfer embryos (Peura et al 1997). It may thorefore be beneficial to increase the cytoplast volume at fusion, especially when cytoplasts have been prepared by oocyte bisection (see Example 1 ).
- zona pellucida free cytoplasts may be fused together before, after, or at the same time as karyoplast fusion using fusion parameters and conditions described above, Alternatively, optimal fusion parameters can be determined by the establishment and evaluation of i ⁇ ofu ⁇ ion contours.
- porcine oocytes are activated prior to enucieation, followed immediately by insertion of the donor nuclei and fusion 3 - 6 hrs after activation, and
- Table 5 shows a summary of embryo transfer results for surgical transfer of reconstituted nuclear transfer porcine embryos produced by techniques of the present invention to synchronized recipients.
- the nuclear tranefer technique was also assessed as to its suitability of the in vitro matured oocyte to service a universal donor.
- the aotivated reconstituted oocytes may be allowed to undergo one round of karyokin ⁇ sis.
- the resulting nuclei can then be used for an additional round of nuclear transfer.
- This second round of nuclear transfer, or serial nuclear transfer, is postulated to Improve the developmental capacity of the donor nuclei.
- re-exposure of the donor nuclei to molecular components in the cytoplasm of the cytoplast may assist in chromatin remodelling that is essential for nuclear reprogramming (Di Borardino 1987; Kwon and Kono 1996).
- the activated reconstituted cytoplasts were cultured in media with cytochaiasin B (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.. 5 bagel) at 39 ⁇ C in 5 0 CO z for 6 hours (Kwon and Kono 199 ⁇ ). Following activation the donor nucleus re- ⁇ ntcrod the ceil cycle and completed karyokinesis. The addition of cytochaiasin B (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.) to the media Inhibited the extrusion of the second PB resulting in the formation of two nuclei.
- cytochaiasin B Sigma Cell Culture, Sigma-Aldrich Pty. Ltd.
- Karyoplasts were prepared from both nuclei and consequently used for a second round of nuclear transfer by placing the karyoplast into the PV space of the cytoplast.
- the cytoplast in the second round of nuclear transfer was usually a zonae pellucida intact, enucleated PN stage fertilised oocyte (aee Example 1). Fusion was induced in a similar manner to that used for the first round of nuclear transfer. Activation was not required.
- nuclear transfer may be performed using karyoplasts from 4-cell nuclear tranefer embryos.
- the nuclear transfer procedure was used as a means of embryo multiplication.
- a ⁇ cytoplasts reconstituted with karyoplasts at the same stage of the cell cycle demonstrate a higher developmental capacity (Cheong et al 1993: Kwon and Kono 1996), in this example metaphase arrested karyoplasts were fused to cytoplasts prepared from enucleated metaphase (Mil) oocytes (see Example 1 ) using ⁇ lectrofusion and activation parameters described above.
- karyoplasts from nuclei in the late G2 stage of the cell cycle (see Example 2). Nuclei within These karyoplasts were allowed to progress- through the cell cycle to mitosis or M phase, prior to fusion but were prevented from further progression through the cell cycle by incubation in nocodazole (Sigma Cell Culture, Sigma-Aldrich Pty. Ltd., 1 ⁇ g/ml).
- PEK pig embryonic kidney
- Electroporation ie the method of choice for introduction of exogenous DNA into a fibroblast cell lines.
- other methods e.g. lipofection
- lipofection e.g. lipofection
- Electroporation parameters for each cell type have to date been optimised using control vector supplied by Peter Mountford. The results of these experiments were validated using the BTI construct (pGallaway). Other targeting constructs will be evaluated as they become available
- Porcine embryonic mesenchymal tissue derived fibroblasts were u ⁇ ed to confirm the feasibility of elimination of ⁇ 1 ,3-galactosyitra ⁇ sfcrasQ activity.
- the cell line, PEM was transferred by electroporation with the pGallaway targeting bector linearized at a unique Xho I restriction site as described in Example 3. 1 x 0° PEM cells were suspended In 0.4 ml of HeBS (20 M HEPES- NaOH pH 7.05, .137 mM NaCl, 5 mM KCI, 0.7 M Na ⁇ HPO*, 6 mM glucose) containing 0.5 mM linearized pGallaway.
- the cell suspension was placed in a 4 mm gap electroporation cuvette and kept at room temperature for 10 min, A 270 V. 960 uF charge was then applied with a Gene Pulser apparatus (Bio-Rad Laboratories).
- the cell suspension was transferred to 10 ml of culture medium and plaled onto 10 cm Petri dish.
- the cells were re-fed culture medium containing 400 ⁇ g ml Geneticin (Life Technologies) and eeiected for 8 - 14 days.
- mutant mutant (primers F238 and RD2) to identify the oolis produoing the mutant transcript expected from the homologous recombination of pGallaway and the endogenous ⁇ 1,3-galactosyltransferase locus.
- Reconstituted oocytes were cultured in 20 ⁇ .l drops ot medium overlaid with paraffin oil (BDH Laboratory Supplies, UK or Sigma Chemical Company, Sigma-Aldrich Pty. Ltd.) under 5% C02 and reduced 02 (5-7%) atmosphere at
- G1 medium was used for the first 48 hr. followed by G2 medium.
- Porcine embryos were incubated in a number of different types of culture media. Two short term culture media were used for embryo collection, manipulation and embryo transfer:
- the embryos were cultured in micro drops of medium overlaid with mineral oil (B H Laboratory Supplies, UK or Sigma Chemical Company, Sigma-Aldrich Pty. Ltd.), in 5%CO a : 5%0 2 : 90%N a atmosphere, at 3R.5 S C.
- the embryos were cultured for up to 7 days before embryo transfer to suitable recipient female.
- H-G1 is a hepes . added version of G1 medium. All chemicals are Sigma, except for BSA (Gibco, or Miles Pe ⁇ tax).
- Concentrated stocks were prepared by dissolving components In sterile MQ H20. Each stock was filtered and stored at 4 ⁇ C for 3 months (Stock AQ ⁇ ). 1 month (Stook D) or one week (Stocks B. DGZ and G).
- Concentrated stocks were prepared by dissolving components in sterile MQ HgO. Each stock was Altered and stored at 4°C for 3 months (Stock A M ), 1 month (Stoc D) or one week (Stocks B. Doe and G).
- Each reagent was added to MQH 2 0 as listed below.
- the pH was measured and adjusted to pH 7.4 with NaOH (approx 50 ⁇ l 1 M NaOH/10ml).
- the medium was filtered and stored at 4°C. Osmoia ⁇ ty should be 269 mOsm.
- Viable offspring can be gonorat ⁇ d from transfer of emoryonic or somatic cell nuclei to enucleated oocytes, Modification of this technology to include transgenic donor nuclei allows the generation ot transgenic animals.
- a unique pig strain was used in the nuclear transfer program.
- the National Institute of Health (MHC/SLA) miniature swine is an inbred strain of swine with a genetically defined major hlstocompatlblllty complex.
- a breeding program was commenced in 1972 to develop a -strain of inbred (MHC/SLA) miniature swine to increase homozygosity at loci associated with the swine lymphocyte antigen complex (Sachs et al., 1976).
- Recipient swine 25 - 40 days pregnant (as confirmed by ultrasoun ⁇ or non return to estrus) were selected for embryo transfer, The following procedure was used to induce synchronisation;
- Prostaglandin F2u analogue followed by 500 IU PMSG Folligon, intervet (Aust) Pty. Ltd. or Pregnecol, Horizon Technology Pty. Ltd.
- Unstimulated, natural cycling recipient pigs were selected for embryo transfer. One cell embryos were transferred 24 hours after detection of estrus. Blastocysts were transferred 5 days after detection of estrus.
- Method 3 Extended Progesterone treatment.
- Natural cycling pigs were treated wilh Altrenogest (Regumate. Roussel-Ulcaf, Paris, France) for 14-1 B days (15-20 mg/animal day) to synchronise estrus cyolcs. Twonty four hours after removal of Regumate (Altrenogest, Hoechst-Roussel) swine were injected with 500 lU of PMSG (Folligon, Intervet (Aust) Pty. Ltd. or Pregnecol, Horizon Technology Pty. Ltd.) followed two days later Injection of 500 lU of hCG (Chorulon, intervet (Aust) Pty. Ltd.) .
- PMSG Folligon, Intervet (Aust) Pty. Ltd. or Pregnecol, Horizon Technology Pty. Ltd.
- Method 4 Synchronization ot estrus of sows after lactation or weaning.
- Oocytes or pronuciear stage embryos were collected through a modified teflon catheter inserted into the oviduct via the infu ⁇ dibullum. Embryos were collected by retrograde flushing with flushing medium (Dulbecco's phosphate buffered saline (Gibco BRL, Life Technologies inc., NY or Trace Bioscience ⁇ Pty. Ltd. [D-PBS] supplemented with 1% fetal calf serum (CSL Limited, Aus), calcium and magnesium).
- flushing medium Dulbecco's phosphate buffered saline (Gibco BRL, Life Technologies inc., NY or Trace Bioscience ⁇ Pty. Ltd. [D-PBS] supplemented with 1% fetal calf serum (CSL Limited, Aus), calcium and magnesium).
- ⁇ Embryos were transferred in short term culture medium.
- One to four cell embryos were transferred to the oviduct of a recipient using a torn cat catheter and 1 ml syringe.
- Eight •cell to blastocyst stage embryos were transferred to the uterus of the recipient using the same equipment.
- Recipients were synchronised to the development stage of the embryos transferred. Improved pregnancy rates were achieved by asynchronous transfer. The estrous cycles of recipient female pigs were programmed 24 hours behind embryo development. Approximately 67% of recipients farrow following such embryo transfer.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU15818/99A AU1581899A (en) | 1997-10-28 | 1998-10-28 | Nuclear transfer for production of transgenic animal embryo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95947397A | 1997-10-28 | 1997-10-28 | |
US08/959,473 | 1997-10-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999021415A1 true WO1999021415A1 (en) | 1999-05-06 |
WO1999021415A9 WO1999021415A9 (en) | 1999-08-19 |
Family
ID=25502074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/022882 WO1999021415A1 (en) | 1997-10-28 | 1998-10-28 | Nuclear transfer for production of transgenic animal embryo |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1581899A (en) |
WO (1) | WO1999021415A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074477A1 (en) * | 1999-06-04 | 2000-12-14 | Istituto Zootecnico E Caseario Per La Sardegna | Process for reconstructing a non-human animal embryo by nuclear transfer and preparing the animal therefrom, and embryos and animals obtained thereby |
WO2001072120A2 (en) * | 2000-03-24 | 2001-10-04 | Geron Corporation | A strategy for maintaining pregnancy |
WO2001073107A1 (en) * | 2000-03-24 | 2001-10-04 | University Of Massachusetts, A Public Institution Of The Commonwealt Of Massachusettes, As Represented By Its Amherst Campus | Prion-free transgenic ungulates |
WO2001088096A2 (en) * | 2000-05-15 | 2001-11-22 | Geron Corporation | Ovine tissue for xenotransplantation |
EP1017423A4 (en) * | 1997-07-03 | 2002-01-30 | Univ Massachusetts | Cloning pigs using donor nuclei from differentiated cells |
US7126039B2 (en) | 2001-03-21 | 2006-10-24 | Geron Corporation | Animal tissue with carbohydrate antigens compatible for human transplantation |
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
US7265262B2 (en) | 2001-03-21 | 2007-09-04 | Roslin Institute (Edinburgh) | Telomerizing nuclear donor cells and improving the efficiency on nuclear transfer |
US7560538B2 (en) | 2003-11-05 | 2009-07-14 | University Of Pittsburgh | Porcine isogloboside 3 synthase protein, cDNA, genomic organization, and regulatory region |
US7795493B2 (en) | 2002-08-21 | 2010-09-14 | Revivicor, Inc. | Porcine animals lacking any expression of functional alpha 1, 3 galactosyltransferase |
US7807863B2 (en) | 2002-11-08 | 2010-10-05 | Kyowa Hakko Kirin Co., Ltd. | Transgenic bovine having reduced prion protein activity and uses thereof |
US7928285B2 (en) | 2004-04-22 | 2011-04-19 | Kyowa Hakko Kirin Co., Ltd. | Method of producing xenogenous antibodies using a bovine |
US8106251B2 (en) | 2002-08-21 | 2012-01-31 | Revivicor, Inc. | Tissue products derived from porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase |
EP3120700A1 (en) * | 2015-07-24 | 2017-01-25 | Ludwig-Maximilians-Universität München | Microinjection into a cell's nucleus following somatic cell nuclear transfer |
US11230697B2 (en) | 2006-09-01 | 2022-01-25 | Therapeutic Human Polyclonals Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
CN114874976A (en) * | 2022-06-23 | 2022-08-09 | 山东大学 | Sodium hyaluronate double-phase gel and application thereof |
CN115161265A (en) * | 2022-08-04 | 2022-10-11 | 山东大学 | Method for obtaining mammalian embryos with same genetic background |
WO2022261434A1 (en) * | 2021-06-10 | 2022-12-15 | The Trustees Of Indiana University | Genetically modified porcine cells, tissue, and animals with reduced human xenoreactivity and methods of using the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995017500A1 (en) * | 1993-12-23 | 1995-06-29 | Abs Global, Inc. | Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals |
US5453366A (en) * | 1990-07-26 | 1995-09-26 | Sims; Michele M. | Method of cloning bovine embryos |
WO1997007669A1 (en) * | 1995-08-31 | 1997-03-06 | Roslin Institute (Edinburgh) | Quiescent cell populations for nuclear transfer |
WO1997016064A1 (en) * | 1995-11-03 | 1997-05-09 | The Mount Sinai Medical Center | Methods and compositions for the reduction of xenotransplantation rejection |
-
1998
- 1998-10-28 WO PCT/US1998/022882 patent/WO1999021415A1/en active Application Filing
- 1998-10-28 AU AU15818/99A patent/AU1581899A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5453366A (en) * | 1990-07-26 | 1995-09-26 | Sims; Michele M. | Method of cloning bovine embryos |
WO1995017500A1 (en) * | 1993-12-23 | 1995-06-29 | Abs Global, Inc. | Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals |
WO1997007669A1 (en) * | 1995-08-31 | 1997-03-06 | Roslin Institute (Edinburgh) | Quiescent cell populations for nuclear transfer |
WO1997016064A1 (en) * | 1995-11-03 | 1997-05-09 | The Mount Sinai Medical Center | Methods and compositions for the reduction of xenotransplantation rejection |
Non-Patent Citations (3)
Title |
---|
LIN LIU ET AL: "Nuclear remodelling an early development in cryopreserved, porcine primordial germ cells following nuclear transfer into in vitro-matured oocytes", INT J. DEV. BIOL., vol. 39, 1995 * |
RANDALLS S. PRATHER ET AL: "Nuclear Transplantation in Early Pig Embryos", BIOLOGY OF REPRODUCTION, vol. 41, 1989, XP002900411, DOI: doi:10.1095/biolreprod41.3.414 * |
VON ANNETTE CLEMENT-SENGEWALD ET AL: "Zur Embryoklonierung von Nutztieren", BERL. M~NCH. TIER{RZTL. WSCHR, vol. 105, 1992, XP002900410 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1017423A4 (en) * | 1997-07-03 | 2002-01-30 | Univ Massachusetts | Cloning pigs using donor nuclei from differentiated cells |
WO2000074477A1 (en) * | 1999-06-04 | 2000-12-14 | Istituto Zootecnico E Caseario Per La Sardegna | Process for reconstructing a non-human animal embryo by nuclear transfer and preparing the animal therefrom, and embryos and animals obtained thereby |
WO2001072120A2 (en) * | 2000-03-24 | 2001-10-04 | Geron Corporation | A strategy for maintaining pregnancy |
WO2001073107A1 (en) * | 2000-03-24 | 2001-10-04 | University Of Massachusetts, A Public Institution Of The Commonwealt Of Massachusettes, As Represented By Its Amherst Campus | Prion-free transgenic ungulates |
WO2001072120A3 (en) * | 2000-03-24 | 2002-02-14 | Geron Corp | A strategy for maintaining pregnancy |
WO2001088096A2 (en) * | 2000-05-15 | 2001-11-22 | Geron Corporation | Ovine tissue for xenotransplantation |
WO2001088096A3 (en) * | 2000-05-15 | 2003-07-10 | Geron Corp | Ovine tissue for xenotransplantation |
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
US7126039B2 (en) | 2001-03-21 | 2006-10-24 | Geron Corporation | Animal tissue with carbohydrate antigens compatible for human transplantation |
US7265262B2 (en) | 2001-03-21 | 2007-09-04 | Roslin Institute (Edinburgh) | Telomerizing nuclear donor cells and improving the efficiency on nuclear transfer |
US11172658B2 (en) | 2002-08-21 | 2021-11-16 | Revivicor, Inc. | Porcine animals lacking expression of functional alpha 1, 3 galactosyltransferase |
US10912863B2 (en) | 2002-08-21 | 2021-02-09 | Revivicor, Inc. | Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase |
US7795493B2 (en) | 2002-08-21 | 2010-09-14 | Revivicor, Inc. | Porcine animals lacking any expression of functional alpha 1, 3 galactosyltransferase |
US10130737B2 (en) | 2002-08-21 | 2018-11-20 | Revivicor, Inc. | Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase |
US8106251B2 (en) | 2002-08-21 | 2012-01-31 | Revivicor, Inc. | Tissue products derived from porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase |
US7807863B2 (en) | 2002-11-08 | 2010-10-05 | Kyowa Hakko Kirin Co., Ltd. | Transgenic bovine having reduced prion protein activity and uses thereof |
US7560538B2 (en) | 2003-11-05 | 2009-07-14 | University Of Pittsburgh | Porcine isogloboside 3 synthase protein, cDNA, genomic organization, and regulatory region |
US7928285B2 (en) | 2004-04-22 | 2011-04-19 | Kyowa Hakko Kirin Co., Ltd. | Method of producing xenogenous antibodies using a bovine |
US11230697B2 (en) | 2006-09-01 | 2022-01-25 | Therapeutic Human Polyclonals Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
EP3120700A1 (en) * | 2015-07-24 | 2017-01-25 | Ludwig-Maximilians-Universität München | Microinjection into a cell's nucleus following somatic cell nuclear transfer |
WO2022261434A1 (en) * | 2021-06-10 | 2022-12-15 | The Trustees Of Indiana University | Genetically modified porcine cells, tissue, and animals with reduced human xenoreactivity and methods of using the same |
CN114874976A (en) * | 2022-06-23 | 2022-08-09 | 山东大学 | Sodium hyaluronate double-phase gel and application thereof |
CN114874976B (en) * | 2022-06-23 | 2024-02-02 | 山东大学 | Sodium hyaluronate biphase gel and application thereof |
CN115161265A (en) * | 2022-08-04 | 2022-10-11 | 山东大学 | Method for obtaining mammalian embryos with same genetic background |
CN115161265B (en) * | 2022-08-04 | 2023-11-24 | 山东大学 | Method for obtaining mammal embryo with same genetic background |
Also Published As
Publication number | Publication date |
---|---|
AU1581899A (en) | 1999-05-17 |
WO1999021415A9 (en) | 1999-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Keefer et al. | Generation of dwarf goat (Capra hircus) clones following nuclear transfer with transfected and nontransfected fetal fibroblasts and in vitro-matured oocytes | |
US20020012660A1 (en) | Method of preparing a somatic cells for nuclear transfer | |
CN106535630A (en) | Multiplex gene editing in swine | |
JP2011188873A (en) | Genetic modification of somatic cell and use thereof | |
WO1999021415A1 (en) | Nuclear transfer for production of transgenic animal embryo | |
US20190223417A1 (en) | Genetically modified animals having increased heat tolerance | |
JP7430414B2 (en) | Transgenic animals and embryos producing modified nucleases | |
JP2018531003A6 (en) | Genetically modified animals with improved heat resistance | |
US7652192B2 (en) | Cloning of transgenic unglulates comprising artificial chromosomes | |
AU2002252076A1 (en) | Cloning of transgenic animals comprising artificial chromosomes | |
US20160160238A1 (en) | Heterozygous modifications of tumor suppressor genes | |
Polejaeva | Generation of genetically engineered livestock using somatic cell nuclear transfer | |
JP4903392B2 (en) | Gene homo-modified mammalian cells, gene homo-modified non-human mammals, and methods for establishing and producing them. | |
WO2022101641A1 (en) | Influenza a-resistant animals having edited anp32 genes | |
AU2005203067A1 (en) | Genetic modification of somatic cells and uses thereof | |
AU2008202720A1 (en) | Genetic modification of somatic cells and uses thereof | |
NZ530425A (en) | Genetic modification of somatic cells and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-64, DESCRIPTION, REPLACED BY NEW PAGES 1-55; PAGES 65-71, CLAIMS, REPLACED BY NEW PAGES 56-64; PAGES 1/15-15/15, DRAWINGS, REPLACED BY NEW PAGES 1/15-15/15; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE (WITH AN UPDATED VERSION OF THE PAMPHLET FRONT PAGE) |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |